ストックスクリーナーアプリを入手
4.29
3.37%
0.14
プレマーケット:
4.35
0.06
+1.40%
前日終値:
$4.15
開ける：
$4.13
24時間の取引高:
2.00M
Relative Volume:
1.00
時価総額：
$1.30B
収益：
$248.37M
当期純損益:
$11.74M
株価収益率:
85.80
EPS:
0.05
ネットキャッシュフロー:
$18.24M
1週間 パフォーマンス:
+4.13%
1か月 パフォーマンス:
-14.20%
6か月 パフォーマンス:
-34.90%
1年 パフォーマンス:
-8.14%
1日の値動き範囲:
$4.13
$4.35
1週間の範囲:
$4.07
$4.35
52週間の値動き範囲:
$4.05
$7.63
Mannkind Corp Stock (MNKD) Company Profile
MNKD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.29 | 1.28B | 248.37M | 11.74M | 18.24M | 0.05 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-10 | 開始されました | Wedbush | Outperform |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-12-19 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-10-10 | 開始されました | Wedbush | Outperform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | 開始されました | Oppenheimer | Outperform |
| 2019-10-25 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-05-14 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
| 2018-02-28 | ダウングレード | Maxim Group | Hold → Sell |
| 2017-11-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2017-10-10 | 開始されました | H.C. Wainwright | Buy |
| 2017-10-06 | 繰り返されました | Maxim Group | Buy |
| 2017-08-11 | 開始されました | Maxim Group | Buy |
| 2016-05-10 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-05-10 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2016-01-06 | 繰り返されました | Piper Jaffray | Underweight |
| 2016-01-06 | 繰り返されました | RBC Capital Mkts | Underperform |
| 2015-11-04 | ダウングレード | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | ダウングレード | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-05-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2015-05-11 | 繰り返されました | MLV & Co | Hold |
| 2015-04-16 | 繰り返されました | RBC Capital Mkts | Outperform |
すべてを表示
Mannkind Corp (MNKD) 最新ニュース
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha
MannKind stock touches 52-week low at $4.34 amid market shifts - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
MannKind at RBC Conference: Strategic Growth and Innovation - Investing.com
MannKind To Present At RBC Capital Markets Conference; Webcast At 8:00 AM ET - Nasdaq
Most adults with type 1 diabetes using inhaled insulin increase daily dose over 30 weeks - Healio
MannKind corp director Steven Binder sells $375,875 in stock By Investing.com - Investing.com Nigeria
MannKind EVP David Thomson sells shares worth $150,597 By Investing.com - Investing.com India
MannKind EVP David Thomson sells shares worth $150,597 - Investing.com
MannKind corp director Steven Binder sells $375,875 in stock - Investing.com
MannKind CMO steps down, transition plan set - Investing.com
MannKind to Present at Upcoming Investor Conferences - The Globe and Mail
MannKind Corporation (NASDAQ:MNKD) Q1 2025 Earnings Call Transcript - Insider Monkey
MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
MannKind: Q1 Earnings Snapshot - MySA
Earnings call transcript: MannKind Q1 2025 revenue beats, stock dips - Investing.com
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Gr - GuruFocus
MannKind (MNKD) Surpasses Q1 Revenue Expectations with Strong Growth | MNKD Stock News - GuruFocus
MannKind Corp Q1 2025 Earnings: EPS Meets Estimates at $0.04, Revenue Surpasses Expectations at $78 Million - GuruFocus
MannKind Corporation Reports First Quarter 2025 Financial Results - TradingView
MANNKIND CORP SEC 10-Q Report - TradingView
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Ex - GuruFocus
MannKind Corp (MNKD) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025 - The Globe and Mail
The Potential Rise in the Price of Mannkind Corp (MNKD) following insiders activity - knoxdaily.com
Solidion Technology Inc’s latest rating changes from various analysts - knoxdaily.com
MNKD (Mannkind Corp) may reap gains as insiders became active recently - knoxdaily.com
Mannkind Corp (MNKD) is looking forward to a strong quarter - Sete News
Is MannKind Corporation (MNKD) the Best Quality Penny Stock to Buy According to Hedge Funds? (READY TO EDIT2) - Insider Monkey
Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MannKind (NASDAQ:MNKD) Upgraded at Mizuho - Defense World
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Mizuho sets MannKind stock Outperform with $12 target - Investing.com
Mizuho sets MannKind stock Outperform with $12 target By Investing.com - Investing.com India
Diabetes Meets Racing: MannKind's Game-Changing Partnership With Type 1 Diabetic IndyCar Star - Stock Titan
MannKind To Support Conor Daly - Speed Sport
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options - Yahoo Finance
FTNT Stock Sees Surge of Approximately 1.11% in Last Five Days - knoxdaily.com
Why It's Worth Keeping An Eye On MannKind - RTTNews
Cantor maintains Overweight rating on MannKind stock at $9 target - Investing.com
Mannkind Corp (MNKD) 財務データ
収益
当期純利益
現金流量
EPS
6.48%
大文字化:
|
ボリューム (24 時間):